<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HBE55B05E7D1344E886CFDF3933A02098" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 3692 IH: Addiction Treatment Access Improvement Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-09-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 3692</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170907">September 7, 2017</action-date><action-desc><sponsor name-id="T000469">Mr. Tonko</sponsor> (for himself and <cosponsor name-id="L000570">Mr. Ben Ray Luján of New Mexico</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Controlled Substances Act to provide for additional flexibility with respect to
			 medication-assisted treatment for opioid use disorders, and for other
			 purposes.</official-title></form>
	<legis-body id="H9F977087AA93435D93625EE8FBE88E54" style="OLC">
 <section id="H014DAD251EAF4F3AA10B62DCDBA38625" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Addiction Treatment Access Improvement Act of 2017</short-title></quote>.</text> </section><section id="HE6AC073852F24780A621DBC3AB6EB2AE"><enum>2.</enum><header>Allowing for more flexibility with respect to medication-assisted treatment for opioid use disorders</header> <subsection id="H98CFE80299554BB4B22FE26F883E5036"><enum>(a)</enum><header>Conforming applicable number</header><text display-inline="yes-display-inline">Subclause (II) of section 303(g)(2)(B)(iii) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(g)(2)(B)(iii)</external-xref>) is amended to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="HA5DB28E1B1C4494E80AC988FF5381777" style="OLC">
 <subclause id="H64E4513224EE4EAA8F699A2893821853" indent="up3"><enum>(II)</enum><text display-inline="yes-display-inline">The applicable number is—</text> <item id="HE067423920BC4943BB461DFCB94E58B9"><enum>(aa)</enum><text>100 if, not sooner than 1 year after the date on which the practitioner submitted the initial notification, the practitioner submits a second notification to the Secretary of the need and intent of the practitioner to treat up to 100 patients; or</text>
 </item><item id="HBE2160096CC749CE83378F48D1F5E5BD"><enum>(bb)</enum><text>275 if the practitioner meets the requirements specified in section 8.610 of title 42, Code of Federal Regulations (or successor regulations).</text></item></subclause><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection><subsection id="HB7865315C5B44AECB31D0A3128078BD7"><enum>(b)</enum><header>Eliminating any time limitation for nurse practitioners, clinical nurse specialists, certified
			 registered nurse anesthetists, certified nurse midwives, and physician
 assistants To become qualifying practitioners</header><text display-inline="yes-display-inline">Section 303(g)(2)(G)(iii)(II) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(g)(2)(G)(iii)(II)</external-xref>) is amended by striking <quote>during the period beginning on the date of enactment of the Comprehensive Addiction and Recovery Act of 2016 and ending on October 1, 2021</quote> and inserting <quote>beginning on the date of enactment of the Comprehensive Addiction and Recovery Act of 2016</quote>.</text>
 </subsection><subsection id="HF45B4578E0F5459B93F656687FF31416"><enum>(c)</enum><header>Definition of qualifying other practitioner</header><text display-inline="yes-display-inline">Clause (iv) of section 303(g)(2)(G) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(g)(2)(G)</external-xref>) is amended by striking <quote>nurse practitioner or physician assistant</quote> each place it appears and inserting <quote>nurse practitioner, clinical nurse specialist, certified registered nurse anesthetist, certified nurse midwife, or physician assistant</quote>.</text>
			</subsection></section></legis-body></bill>


